In a worldwide multicenter collaboration, our group gathered several cases of APL-like AMLs, and those ATRA-resistant, harboring ZBTB16-RARA and STAT5B-RARA rearrangements, presented an overall survival (OS) and event-free survival (EFS) of 60.9 and 56.7% at 12 months, respectively. This evidence concerns the gene RARA and acute promyelocytic leukemia.